This study is designed to evaluate the efficacy, safety, and tolerability of oxcarbazepine versus placebo. The total duration of study medication exposure is 19-weeks. The study consists of three phases; a 4-week Single-blind Baseline Phase, a 14-week Double-blind Treatment Phase, and a 1-week Down-titration Phase. Subjects who have completed at least 4 weeks of treatment also have the option of rolling over into a 3-month open label extension.

Study Qualifications:

• Subjects MUST live in Dallas, Texas, and nearby areas.
• Subjects can be male or female and must between the age of 16 and 65 years old.
• Subjects must have a clinical diagnosis of migraine headaches with and without aura for at least one year prior to study entry.
• Subjects must have had their first migraine headache at or prior to 50 years of age.
• Subjects must experience 3 to 9 migraine attacks per month and must be able to distinguish between migraine and other types of headaches.
• Subjects must not have a significant history of medical disease within the previous two years which could interfere with their participation.
• Subjects must not use drugs excessively to treat non-migraine headaches (more than three days per week).
• Subjects must not have a seizure disorder.
• Subjects must not previously failed more than three adequate courses of an effective migraine preventive treatment.

Contact:

Bonnie Blesse
Anodyne Pain Center
5446 Glen Lake Drive
Dallas, TX 75231
Telephone: 214-783-5797
Fax: 214-750-6671
Email: bblesse@swbell.net